Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C07
ORGANIC CHEMISTRY
Load children
C07C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
Load children
311/00
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/50
Compounds containing any of the groups , X being a hetero atom, Y being any atom
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/54
either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/57
having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/58
having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
Filter patents View analytics View as hierarchy Open in page

C07C311/58

Thromboxane receptor antagonists
09630915 · 2017-04-25 · ·

The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP) or TPbeta (TP) receptor subtype.

THROMBOXANE RECEPTOR ANTAGONISTS
20170057913 · 2017-03-02 ·

The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP) or TPbeta (TP) receptor subtype.

THROMBOXANE RECEPTOR ANTAGONISTS
20170057913 · 2017-03-02 ·

The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP) or TPbeta (TP) receptor subtype.

N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections
12616670 · 2026-05-05 · ·

The present invention related to novel inhibitors of metallo--lactamases of formula (I) ##STR00001## wherein R.sup.1 is an optionally substituted aryl group of an optionally substituted heteroaryl group, and the use thereof in the treatment of bacterial infections, especially in combination with -lactam antibiotics.

N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections
12616670 · 2026-05-05 · ·

The present invention related to novel inhibitors of metallo--lactamases of formula (I) ##STR00001## wherein R.sup.1 is an optionally substituted aryl group of an optionally substituted heteroaryl group, and the use thereof in the treatment of bacterial infections, especially in combination with -lactam antibiotics.